[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantation of a dual-chamber pacemaker", "Addition of disopyramide", "Cardiac resynchronization therapy"], "answer": "D", "answer_index": 3, "explanation": "Addition of disopyramide is the most appropriate next step as it is recommended for symptomatic hypertrophic cardiomyopathy with obstruction refractory to beta-blockers, acting as a negative inotrope to reduce the gradient. Alcohol septal ablation and surgical myectomy are invasive options considered only after failure of medical therapy including disopyramide. Pacemaker implantation and cardiac resynchronization therapy are not first-line for outflow tract obstruction in this context.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item presents a classic stepwise management scenario for obstructive hypertrophic cardiomyopathy (HOCM). The patient has severe resting obstruction (80 mmHg gradient) and symptoms (syncope) despite beta-blocker therapy. Current guidelines (AHA/ACC/ESC) recommend a trial of disopyramide (added to beta-blockers) for patients who remain symptomatic on first-line agents before proceeding to invasive Septal Reduction Therapy (SRT). Surgical myectomy (Option B) and alcohol septal ablation (Option A) are indicated only for drug-refractory patients (those failing beta-blockers/CCBs *and* disopyramide) or those with specific contraindications to medical therapy. While recurrent syncope is a risk factor for sudden cardiac death that warrants risk stratification for an ICD, the options provided focus on gradient/symptom management. Among the choices, adding disopyramide is the distinct, guideline-appropriate next step in the therapeutic hierarchy. Options C and E are not first-line treatments for obstruction. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item presents a classic stepwise management scenario for obstructive hypertrophic cardiomyopathy (HOCM). The patient has severe resting obstruction (80 mmHg gradient) and symptoms (syncope) despite beta-blocker therapy. Current guidelines (AHA/ACC/ESC) recommend a trial of disopyramide (added to beta-blockers) for patients who remain symptomatic on first-line agents before proceeding to invasive Septal Reduction Therapy (SRT). Surgical myectomy (Option B) and alcohol septal ablation (Option A) are indicated only for drug-refractory patients (those failing beta-blockers/CCBs *and* disopyramide) or those with specific contraindications to medical therapy. While recurrent syncope is a risk factor for sudden cardiac death that warrants risk stratification for an ICD, the options provided focus on gradient/symptom management. Among the choices, adding disopyramide is the distinct, guideline-appropriate next step in the therapeutic hierarchy. Options C and E are not first-line treatments for obstruction. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-002", "question": "A 4-year-old boy with a history of recurrent urinary tract infections is found to have vesicoureteral reflux on voiding cystourethrogram. Renal ultrasound shows mild hydronephrosis. Despite prophylactic antibiotics, he develops breakthrough infections. Genetic evaluation reveals a mutation in the PAX2 gene. What is the most likely associated syndrome?", "options": ["Denys-Drash syndrome", "Renal coloboma syndrome", "Branchio-oto-renal syndrome", "Alport syndrome", "Frasier syndrome"], "answer": "B", "answer_index": 1, "explanation": "Renal coloboma syndrome is associated with PAX2 mutations, characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve colobomas. Denys-Drash and Frasier syndromes involve WT1 mutations, while Alport syndrome relates to collagen IV defects. Branchio-oto-renal syndrome is linked to EYA1 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best. The question relies on a definitive genetic marker (PAX2 mutation) which is the established etiology for Renal Coloboma Syndrome (also known as Papillorenal Syndrome). The clinical presentation of VUR and renal anomalies is consistent with this diagnosis, even without the explicit mention of colobomas in the vignette, as the genetic finding is diagnostic. The distractors are incorrect based on their well-established genetic associations: Denys-Drash and Frasier syndromes are caused by WT1 mutations, Branchio-oto-renal syndrome by EYA1/SIX1/SIX5 mutations, and Alport syndrome by COL4A mutations. The item is medically accurate and logically sound, presenting a unique best answer derived directly from the provided genetic data.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. The question relies on a definitive genetic marker (PAX2 mutation) which is the established etiology for Renal Coloboma Syndrome (also known as Papillorenal Syndrome). The clinical presentation of VUR and renal anomalies is consistent with this diagnosis, even without the explicit mention of colobomas in the vignette, as the genetic finding is diagnostic. The distractors are incorrect based on their well-established genetic associations: Denys-Drash and Frasier syndromes are caused by WT1 mutations, Branchio-oto-renal syndrome by EYA1/SIX1/SIX5 mutations, and Alport syndrome by COL4A mutations. The item is medically accurate and logically sound, presenting a unique best answer derived directly from the provided genetic data.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-003", "question": "In the emergency department, a 32-year-old woman presents with acute chest pain and dyspnea following a long-haul flight. CT pulmonary angiography confirms a segmental pulmonary embolism. She has a history of oral contraceptive use and a positive family history for thrombophilia. Laboratory testing shows elevated factor VIII levels. What is the most appropriate initial anticoagulant therapy?", "options": ["Low-molecular-weight heparin followed by warfarin", "Direct oral anticoagulant such as rivaroxaban", "Unfractionated heparin with thrombolysis", "Fondaparinux monotherapy", "Aspirin and clopidogrel combination"], "answer": "B", "answer_index": 1, "explanation": "Direct oral anticoagulants like rivaroxaban are preferred for initial treatment of pulmonary embolism in non-pregnant patients without severe renal impairment or active cancer. Low-molecular-weight heparin followed by warfarin is an alternative but less convenient. Thrombolysis is reserved for hemodynamically unstable cases, and antiplatelet therapy is insufficient for venous thromboembolism.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict on keyed answer: Correct best. The vignette describes a patient with acute pulmonary embolism (PE). While hemodynamic vitals are not explicitly provided, the description of a 'segmental' PE and the absence of shock indicators implies hemodynamic stability. Current major guidelines (e.g., CHEST 2021) recommend Direct Oral Anticoagulants (DOACs) like rivaroxaban over Vitamin K Antagonists (warfarin) for the initial and long-term treatment of VTE in non-cancer patients. Elevated Factor VIII is a prothrombotic risk factor but does not contraindicate DOACs (unlike high-risk antiphospholipid syndrome). Therefore, Option B is the best answer. Option A (LMWH/Warfarin) is a valid alternative but is generally second-line due to convenience and bleeding risk considerations. Option C (Thrombolysis) is contraindicated in stable patients. Option D (Fondaparinux) is typically a bridge to oral therapy rather than a standalone monotherapy for the full treatment course in this context. Option E is ineffective for VTE. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict on keyed answer: Correct best. The vignette describes a patient with acute pulmonary embolism (PE). While hemodynamic vitals are not explicitly provided, the description of a 'segmental' PE and the absence of shock indicators implies hemodynamic stability. Current major guidelines (e.g., CHEST 2021) recommend Direct Oral Anticoagulants (DOACs) like rivaroxaban over Vitamin K Antagonists (warfarin) for the initial and long-term treatment of VTE in non-cancer patients. Elevated Factor VIII is a prothrombotic risk factor but does not contraindicate DOACs (unlike high-risk antiphospholipid syndrome). Therefore, Option B is the best answer. Option A (LMWH/Warfarin) is a valid alternative but is generally second-line due to convenience and bleeding risk considerations. Option C (Thrombolysis) is contraindicated in stable patients. Option D (Fondaparinux) is typically a bridge to oral therapy rather than a standalone monotherapy for the full treatment course in this context. Option E is ineffective for VTE. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-004", "question": "A 45-year-old woman presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. Laboratory tests show positive anti-citrullinated protein antibodies and elevated inflammatory markers. Despite methotrexate therapy, her disease progresses. Genetic testing reveals a mutation in the NLRP3 gene. What is the most likely diagnosis?", "options": ["Rheumatoid arthritis", "Cryopyrin-associated periodic syndrome", "Adult-onset Still's disease", "BehÃ§et's disease", "Systemic lupus erythematosus"], "answer": "B", "answer_index": 1, "explanation": "Cryopyrin-associated periodic syndrome involves NLRP3 mutations, presenting with arthritis, rash, and autoinflammatory features that may mimic rheumatoid arthritis but respond poorly to standard DMARDs. Rheumatoid arthritis typically lacks this genetic mutation and responds to methotrexate. Adult-onset Still's disease and others do not feature NLRP3 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: C (Contradiction). Verdict: No defensible answer due to internal inconsistency. The vignette presents a fatal medical contradiction. The patient has positive anti-citrullinated protein antibodies (ACPA), which are highly specific (>95%) for Rheumatoid Arthritis (Option A) and are not a feature of autoinflammatory diseases like CAPS. However, the patient also has a mutation in the NLRP3 gene, which is the defining cause of Cryopyrin-Associated Periodic Syndromes (Option B). The stem forces a choice between the serological diagnosis (RA) and the genetic diagnosis (CAPS). While the author intends CAPS (due to the gene and methotrexate failure), the presence of ACPA makes the patient technically fulfill criteria for RA, and CAPS patients are seronegative. A single patient cannot be the 'most likely diagnosis' for CAPS while having RA-specific antibodies unless they have two concurrent diseases, which the question does not allow. Minimal fix: Change 'positive anti-citrullinated protein antibodies' to 'negative autoantibodies' to align with the CAPS diagnosis.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (Contradiction). Verdict: No defensible answer due to internal inconsistency. The vignette presents a fatal medical contradiction. The patient has positive anti-citrullinated protein antibodies (ACPA), which are highly specific (>95%) for Rheumatoid Arthritis (Option A) and are not a feature of autoinflammatory diseases like CAPS. However, the patient also has a mutation in the NLRP3 gene, which is the defining cause of Cryopyrin-Associated Periodic Syndromes (Option B). The stem forces a choice between the serological diagnosis (RA) and the genetic diagnosis (CAPS). While the author intends CAPS (due to the gene and methotrexate failure), the presence of ACPA makes the patient technically fulfill criteria for RA, and CAPS patients are seronegative. A single patient cannot be the 'most likely diagnosis' for CAPS while having RA-specific antibodies unless they have two concurrent diseases, which the question does not allow. Minimal fix: Change 'positive anti-citrullinated protein antibodies' to 'negative autoantibodies' to align with the CAPS diagnosis.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-005", "question": "A 28-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite insulin dose adjustments. Continuous glucose monitoring shows nocturnal hypoglycemia. Laboratory evaluation reveals elevated proinsulin levels and a low C-peptide. What is the most likely underlying mechanism?", "options": ["Insulinoma", "Factitious hypoglycemia from exogenous insulin", "Adrenal insufficiency", "Autoimmune hypoglycemia", "Nesidioblastosis"], "answer": "B", "answer_index": 1, "explanation": "Factitious hypoglycemia from exogenous insulin is indicated by low C-peptide and elevated proinsulin due to suppressed endogenous insulin production. Insulinoma would show high C-peptide and proinsulin. Adrenal insufficiency typically causes hyperglycemia, and autoimmune hypoglycemia involves insulin antibodies with variable C-peptide.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: C (Contradiction)\\nVerdict on keyed answer: No defensible answer\\n\\nThe item presents a physiological contradiction. The vignette describes a patient with Type 1 Diabetes Mellitus (T1DM) and 'low C-peptide' (consistent with T1DM or exogenous insulin) but also 'elevated proinsulin.' This combination is medically incoherent. In T1DM, beta-cell destruction results in the absence of both C-peptide and proinsulin. If the patient were taking exogenous insulin (Option B, the key), endogenous beta-cell secretion would be suppressed, resulting in low C-peptide and low proinsulin. Elevated proinsulin is a marker of endogenous hyperinsulinism (e.g., insulinoma), which would invariably present with elevated C-peptide. The author's rationale incorrectly claims that exogenous insulin leads to elevated proinsulin; in reality, it suppresses it. Because the stem findings (Low C-peptide + High Proinsulin) are mutually exclusive and rule out all provided options, the item is unsolvable.\\n\\nMinimal fix: Change 'elevated proinsulin' to 'low proinsulin' in the stem. This would align with the profile of factitious hypoglycemia from exogenous insulin (Low C-peptide, Low Proinsulin).\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (Contradiction)\nVerdict on keyed answer: No defensible answer\n\nThe item presents a physiological contradiction. The vignette describes a patient with Type 1 Diabetes Mellitus (T1DM) and 'low C-peptide' (consistent with T1DM or exogenous insulin) but also 'elevated proinsulin.' This combination is medically incoherent. In T1DM, beta-cell destruction results in the absence of both C-peptide and proinsulin. If the patient were taking exogenous insulin (Option B, the key), endogenous beta-cell secretion would be suppressed, resulting in low C-peptide and low proinsulin. Elevated proinsulin is a marker of endogenous hyperinsulinism (e.g., insulinoma), which would invariably present with elevated C-peptide. The author's rationale incorrectly claims that exogenous insulin leads to elevated proinsulin; in reality, it suppresses it. Because the stem findings (Low C-peptide + High Proinsulin) are mutually exclusive and rule out all provided options, the item is unsolvable.\n\nMinimal fix: Change 'elevated proinsulin' to 'low proinsulin' in the stem. This would align with the profile of factitious hypoglycemia from exogenous insulin (Low C-peptide, Low Proinsulin).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-006", "question": "A 65-year-old man with ischemic cardiomyopathy and an ejection fraction of 25% develops sustained ventricular tachycardia. He is hemodynamically stable. Electrophysiology study identifies a reentrant circuit in the infarct border zone. Despite amiodarone therapy, episodes recur. What is the most appropriate next intervention?", "options": ["Catheter ablation", "Implantable cardioverter-defibrillator upgrade to biventricular", "Addition of mexiletine", "Stellate ganglionectomy", "Cardiac sympathetic denervation"], "answer": "A", "answer_index": 0, "explanation": "Catheter ablation is the most appropriate for recurrent ventricular tachycardia in ischemic cardiomyopathy refractory to antiarrhythmic drugs, targeting the reentrant circuit. ICD upgrade addresses heart failure but not arrhythmia substrate directly. Mexiletine addition is less effective for scar-related VT, and surgical options like ganglionectomy are reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question describes a patient with ischemic cardiomyopathy and recurrent sustained ventricular tachycardia (VT) despite amiodarone therapy. The mechanism is identified as a reentrant circuit in the infarct border zone. According to major guidelines (AHA/ACC/HRS) and the VANISH trial, catheter ablation is the recommended next intervention for patients with ischemic cardiomyopathy and recurrent VT who have failed antiarrhythmic drug therapy. Ablation is superior to escalating antiarrhythmic drugs (like adding mexiletine, Option C) in reducing the composite endpoint of death, VT storm, or appropriate ICD shocks. Cardiac sympathetic denervation (Options D/E) is typically reserved for cases refractory to both medications and ablation. Biventricular pacing (Option B) is indicated for heart failure with specific QRS criteria (dyssynchrony), which are not provided here, and does not directly treat the arrhythmia substrate. The item is medically accurate, logically sound, and the key (A) is the unique best answer.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question describes a patient with ischemic cardiomyopathy and recurrent sustained ventricular tachycardia (VT) despite amiodarone therapy. The mechanism is identified as a reentrant circuit in the infarct border zone. According to major guidelines (AHA/ACC/HRS) and the VANISH trial, catheter ablation is the recommended next intervention for patients with ischemic cardiomyopathy and recurrent VT who have failed antiarrhythmic drug therapy. Ablation is superior to escalating antiarrhythmic drugs (like adding mexiletine, Option C) in reducing the composite endpoint of death, VT storm, or appropriate ICD shocks. Cardiac sympathetic denervation (Options D/E) is typically reserved for cases refractory to both medications and ablation. Biventricular pacing (Option B) is indicated for heart failure with specific QRS criteria (dyssynchrony), which are not provided here, and does not directly treat the arrhythmia substrate. The item is medically accurate, logically sound, and the key (A) is the unique best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-007", "question": "An 8-year-old girl with short stature and failure to thrive undergoes evaluation. Bone age is delayed, and laboratory tests show low IGF-1 with normal growth hormone stimulation. Genetic testing reveals a mutation in the IGF1R gene. What is the most appropriate management strategy?", "options": ["Recombinant growth hormone therapy", "IGF-1 replacement therapy", "Nutritional supplementation", "Thyroid hormone replacement", "Corticosteroid therapy"], "answer": "B", "answer_index": 1, "explanation": "IGF-1 replacement therapy is indicated for IGF1R mutations causing primary IGF-1 deficiency resistant to growth hormone. Recombinant growth hormone would be ineffective due to receptor defect. Nutritional or hormonal supplements like thyroid or corticosteroids do not address the underlying IGF-1 resistance.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: C (Contradiction)\\nVerdict on keyed answer: No defensible answer / Medically incorrect\\n\\nThe item contains a fundamental medical contradiction. The vignette describes a patient with 'low IGF-1' but a genetic mutation in the 'IGF1R gene' (IGF-1 receptor). In medical reality, IGF1R mutations cause IGF-1 resistance, which typically results in elevated or normal serum IGF-1 levels (due to impaired feedback), not low levels. Low IGF-1 with normal GH is characteristic of Primary IGF-1 Deficiency (e.g., Laron syndrome due to GHR mutations, or IGF1 gene deletion). Furthermore, the keyed answer (IGF-1 replacement) is the treatment for Primary IGF-1 Deficiency (ligand deficit or GH receptor defect), not for IGF1R mutations (receptor defect). Treating a defective receptor with its ligand is generally ineffective; recombinant GH is the typical (though variable) therapy for IGF1R mutations. The author has conflated IGF1R mutations with conditions causing IGF-1 deficiency. As written, the labs contradict the genetics, and the treatment contradicts the genetics.\\n\\nMinimal fix: Change 'IGF1R gene' to 'IGF1 gene' (or 'GHR gene') to align with the low IGF-1 findings and the indication for IGF-1 replacement therapy.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (Contradiction)\nVerdict on keyed answer: No defensible answer / Medically incorrect\n\nThe item contains a fundamental medical contradiction. The vignette describes a patient with 'low IGF-1' but a genetic mutation in the 'IGF1R gene' (IGF-1 receptor). In medical reality, IGF1R mutations cause IGF-1 resistance, which typically results in elevated or normal serum IGF-1 levels (due to impaired feedback), not low levels. Low IGF-1 with normal GH is characteristic of Primary IGF-1 Deficiency (e.g., Laron syndrome due to GHR mutations, or IGF1 gene deletion). Furthermore, the keyed answer (IGF-1 replacement) is the treatment for Primary IGF-1 Deficiency (ligand deficit or GH receptor defect), not for IGF1R mutations (receptor defect). Treating a defective receptor with its ligand is generally ineffective; recombinant GH is the typical (though variable) therapy for IGF1R mutations. The author has conflated IGF1R mutations with conditions causing IGF-1 deficiency. As written, the labs contradict the genetics, and the treatment contradicts the genetics.\n\nMinimal fix: Change 'IGF1R gene' to 'IGF1 gene' (or 'GHR gene') to align with the low IGF-1 findings and the indication for IGF-1 replacement therapy.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-008", "question": "In the emergency department, a 50-year-old man presents with severe abdominal pain and vomiting. CT scan shows acute pancreatitis with necrosis. He develops hypotension and acute kidney injury. Serum triglycerides are 1200 mg/dL. What is the most appropriate initial management for the hypertriglyceridemia?", "options": ["Plasmapheresis", "Insulin infusion", "Fibrates", "Niacin", "Statins"], "answer": "B", "answer_index": 1, "explanation": "Insulin infusion effectively lowers triglycerides in hypertriglyceridemic pancreatitis by enhancing lipoprotein lipase activity. Plasmapheresis is reserved for severe cases not responding to insulin. Fibrates, niacin, and statins are long-term therapies not suitable for acute management.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes severe acute pancreatitis due to hypertriglyceridemia (TG > 1000 mg/dL) complicated by organ failure (hypotension, AKI). The question asks for the most appropriate *initial* management of the hypertriglyceridemia. Options C (Fibrates), D (Niacin), and E (Statins) are oral agents for chronic lipid management and have no role in the acute lowering of triglycerides in a crisis. The decision is between Insulin infusion (B) and Plasmapheresis (A). While plasmapheresis is a valid consideration for severe cases with organ failure, it is invasive, resource-dependent, and requires time to initiate. Insulin infusion (often with dextrose) is universally available, can be started immediately, and effectively activates lipoprotein lipase to lower TG levels. Furthermore, comparative data (including Cochrane reviews) have not definitively demonstrated a mortality benefit of plasmapheresis over conservative management with insulin. Therefore, insulin is the most defensible 'initial' step for a general medical board exam, making B the correct answer. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes severe acute pancreatitis due to hypertriglyceridemia (TG > 1000 mg/dL) complicated by organ failure (hypotension, AKI). The question asks for the most appropriate *initial* management of the hypertriglyceridemia. Options C (Fibrates), D (Niacin), and E (Statins) are oral agents for chronic lipid management and have no role in the acute lowering of triglycerides in a crisis. The decision is between Insulin infusion (B) and Plasmapheresis (A). While plasmapheresis is a valid consideration for severe cases with organ failure, it is invasive, resource-dependent, and requires time to initiate. Insulin infusion (often with dextrose) is universally available, can be started immediately, and effectively activates lipoprotein lipase to lower TG levels. Furthermore, comparative data (including Cochrane reviews) have not definitively demonstrated a mortality benefit of plasmapheresis over conservative management with insulin. Therefore, insulin is the most defensible 'initial' step for a general medical board exam, making B the correct answer. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-009", "question": "A 35-year-old woman with seropositive rheumatoid arthritis on infliximab develops fever, weight loss, and lymphadenopathy. Biopsy shows non-caseating granulomas. Serum angiotensin-converting enzyme is elevated. What is the most likely diagnosis?", "options": ["Tuberculosis reactivation", "Infliximab-induced sarcoidosis", "Lymphoma", "Fungal infection", "Amyloidosis"], "answer": "B", "answer_index": 1, "explanation": "Infliximab-induced sarcoidosis is a rare complication of TNF inhibitors, presenting with granulomatous inflammation mimicking sarcoidosis. Tuberculosis would show caseating granulomas and positive cultures. Lymphoma or infections are differentials but less likely without specific evidence.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question describes a patient on a TNF-inhibitor (infliximab) presenting with systemic symptoms and lymphadenopathy. The key discriminators are the biopsy finding of \\\"non-caseating granulomas\\\" and \\\"elevated serum ACE.\\\" While Tuberculosis (Option A) is a major risk for patients on TNF-inhibitors and must be ruled out clinically, it classically presents with *caseating* granulomas. The specific combination of non-caseating granulomas and elevated ACE is the board-exam signature for Sarcoidosis. In the context of anti-TNF therapy, this points to the well-documented paradoxical adverse effect: Infliximab-induced sarcoidosis (Option B). Although fungal infections (Option D) can cause granulomas, the stem lacks geographic cues (e.g., Ohio River Valley) and the ACE/non-caseating pattern specifically targets the sarcoid diagnosis. Lymphoma (Option C) would show malignant cells on biopsy. Therefore, despite the statistical rarity of the adverse event compared to infection, the specific pathologic and lab details make Option B the unique best answer in a testing context.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question describes a patient on a TNF-inhibitor (infliximab) presenting with systemic symptoms and lymphadenopathy. The key discriminators are the biopsy finding of \"non-caseating granulomas\" and \"elevated serum ACE.\" While Tuberculosis (Option A) is a major risk for patients on TNF-inhibitors and must be ruled out clinically, it classically presents with *caseating* granulomas. The specific combination of non-caseating granulomas and elevated ACE is the board-exam signature for Sarcoidosis. In the context of anti-TNF therapy, this points to the well-documented paradoxical adverse effect: Infliximab-induced sarcoidosis (Option B). Although fungal infections (Option D) can cause granulomas, the stem lacks geographic cues (e.g., Ohio River Valley) and the ACE/non-caseating pattern specifically targets the sarcoid diagnosis. Lymphoma (Option C) would show malignant cells on biopsy. Therefore, despite the statistical rarity of the adverse event compared to infection, the specific pathologic and lab details make Option B the unique best answer in a testing context.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-010", "question": "A 42-year-old woman with acromegaly undergoes transsphenoidal surgery, but IGF-1 levels remain elevated postoperatively. She declines further surgery. What is the most appropriate pharmacologic therapy?", "options": ["Cabergoline", "Pegvisomant", "Octreotide", "Pasireotide", "Bromocriptine"], "answer": "B", "answer_index": 1, "explanation": "Pegvisomant, a growth hormone receptor antagonist, is the most effective for normalizing IGF-1 in acromegaly resistant to surgery and somatostatin analogs. Octreotide and pasireotide are somatostatin analogs that may not suffice post-surgery. Dopamine agonists like cabergoline or bromocriptine are less potent for pure GH-secreting adenomas.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with persistent acromegaly after transsphenoidal surgery who requires pharmacologic therapy. According to standard clinical guidelines (e.g., Endocrine Society), the first-line medical treatment for persistent disease is a Somatostatin Receptor Ligand (SRL) such as Octreotide (Option C). Pegvisomant (Option B) is typically reserved as a second-line agent for patients who do not respond adequately to SRLs. The provided rationale justifies Option B by claiming the patient is 'resistant to... somatostatin analogs,' a critical clinical detail that is entirely absent from the question stem. As written, the patient is naive to medical therapy; thus, Octreotide is the most appropriate initial choice. The item is miskeyed because the correct answer based on the provided text is C, while the key is B. To make the key correct, the stem must explicitly state that the patient has already failed therapy with a somatostatin analog.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with persistent acromegaly after transsphenoidal surgery who requires pharmacologic therapy. According to standard clinical guidelines (e.g., Endocrine Society), the first-line medical treatment for persistent disease is a Somatostatin Receptor Ligand (SRL) such as Octreotide (Option C). Pegvisomant (Option B) is typically reserved as a second-line agent for patients who do not respond adequately to SRLs. The provided rationale justifies Option B by claiming the patient is 'resistant to... somatostatin analogs,' a critical clinical detail that is entirely absent from the question stem. As written, the patient is naive to medical therapy; thus, Octreotide is the most appropriate initial choice. The item is miskeyed because the correct answer based on the provided text is C, while the key is B. To make the key correct, the stem must explicitly state that the patient has already failed therapy with a somatostatin analog.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}]